Use of nivolumab in elderly patients with advanced squamous non–small-cell lung cancer: results from the Italian cohort of an expanded access programme
01 Pubblicazione su rivista
Grossi Francesco, Crinò Lucio, Logroscino Antonio, Canova Stefania, Delmonte Angelo, Melotti Barbara, Proto Claudia, Gelibter Alain, Cappuzzo Federico, Turci Daniele, Gamucci Teresa, Antonelli Paola, Marchetti Paolo, Santoro Armando, Giusti Sabrina, Di Costanzo Francesco, Giustini Lucio, Del Conte Alessandro, Livi Lorenzo, Giannarelli Diana, de Marinis Filippo
ISSN: 0959-8049
Aim: This analysis evaluated the efficacy and safety of nivolumab, an immune checkpoint inhibitor, in elderly patients with stage IIIB or IV squamous non–small-cell lung cancer (NSCLC) enrolled in the expanded access programme (EAP) in Italy. Methods: Nivolumab was available on physician request. Safety data included adverse events (AEs). Efficacy data included investigator-assessed tumour response, progression date and survival information. Results were analysed for patients aged